Flory Kreutter, MD
Family Medicine · Denver, CONPI 1538115134
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. GSK accounts for 93.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $12,069 and has fallen 99.2% since, to $92 in 2021. Among family medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $154.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$12K
- AstraZeneca$317
- Amgen$109
- AbbVie$102
- Merck$99
- Johnson & Johnson$47
- plus $170 from 9 others
Across 37 payments — averaging $2832.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$51K
- Teva Pharmaceuticals USA, Inc.$28K
- Sanofi US Services Inc.$12K
- Astrazeneca AB$9K
- Genentech, Inc.$5K
What the payments were for
- Consulting fees$7,30155%
- Speaking & faculty fees$2,50019%
- Travel & lodging$1,87214%
- Food & beverage$1,62912%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $12,465 |
| AstraZeneca | 20 | $317 |
| Amgen | 6 | $109 |
| AbbVie | 6 | $102 |
| Merck | 7 | $99 |
| Johnson & Johnson(2 entities) | 3 | $47 |
| Boehringer Ingelheim | 3 | $41 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Seqirus USA Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Novo Nordisk | 1 | $12 |
| Aytu Biopharma, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$7,199
- NUCALA$3,920
How this compares
$13,308 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $97,545 |
| JardianceEmpagliflozin | 18 | $32,992 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $27,424 |
| TrulicityDulaglutide | 14 | $13,961 |
| EliquisApixaban | 11 | $13,852 |
| Atorvastatin Calcium | 275 | $1,820 |
| Gabapentin | 70 | $1,338 |
| Rosuvastatin Calcium | 118 | $1,316 |
| Levothyroxine Sodium | 140 | $1,093 |
| Amlodipine Besylate | 155 | $761 |
| Bupropion XlBupropion Hcl | 26 | $747 |
| Alendronate Sodium | 89 | $620 |
| FenofibrateFenofibrate Nanocrystallized | 24 | $607 |
| Hydrochlorothiazide | 129 | $560 |
| Lisinopril | 123 | $543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $12 | $97,54564 claims |
| Boehringer IngelheimJardiance | $41 | $32,99218 claims |
| GSKAnoro Ellipta | $12,465 | $27,42425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Denver
- Ethan LazarusDenver$688K
- Mark DeutchmanDenver$258K
- Mia ScottDenver$53K
- Khoi NguyenDenver$13K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.